These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 7998774)

  • 1. Complex I, iron, and ferritin in Parkinson's disease substantia nigra.
    Mann VM; Cooper JM; Daniel SE; Srai K; Jenner P; Marsden CD; Schapira AH
    Ann Neurol; 1994 Dec; 36(6):876-81. PubMed ID: 7998774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease.
    Dexter DT; Sian J; Rose S; Hindmarsh JG; Mann VM; Cooper JM; Wells FR; Daniel SE; Lees AJ; Schapira AH
    Ann Neurol; 1994 Jan; 35(1):38-44. PubMed ID: 8285590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron and ferritin in substantia nigra in Parkinson's disease.
    Jellinger KA; Kienzl E; Rumpelmaier G; Paulus W; Riederer P; Stachelberger H; Youdim MB; Ben-Shachar D
    Adv Neurol; 1993; 60():267-72. PubMed ID: 8420142
    [No Abstract]   [Full Text] [Related]  

  • 4. Iron histochemistry of the substantia nigra in Parkinson's disease.
    Morris CM; Edwardson JA
    Neurodegeneration; 1994 Dec; 3(4):277-82. PubMed ID: 7842298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ELISA reveals a difference in the structure of substantia nigra ferritin in Parkinson's disease and incidental Lewy body compared to control.
    Koziorowski D; Friedman A; Arosio P; Santambrogio P; Dziewulska D
    Parkinsonism Relat Disord; 2007 May; 13(4):214-8. PubMed ID: 17275395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases.
    Gu M; Owen AD; Toffa SE; Cooper JM; Dexter DT; Jenner P; Marsden CD; Schapira AH
    J Neurol Sci; 1998 Jun; 158(1):24-9. PubMed ID: 9667773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of nitrosyl complexes in human substantia nigra, in relation to Parkinson's disease.
    Shergill JK; Cammack R; Cooper CE; Cooper JM; Mann VM; Schapira AH
    Biochem Biophys Res Commun; 1996 Nov; 228(2):298-305. PubMed ID: 8920909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrapallidal lipopolysaccharide injection increases iron and ferritin levels in glia of the rat substantia nigra and induces locomotor deficits.
    Zhang J; Stanton DM; Nguyen XV; Liu M; Zhang Z; Gash D; Bing G
    Neuroscience; 2005; 135(3):829-38. PubMed ID: 16165292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia.
    Sian J; Dexter DT; Lees AJ; Daniel S; Agid Y; Javoy-Agid F; Jenner P; Marsden CD
    Ann Neurol; 1994 Sep; 36(3):348-55. PubMed ID: 8080242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron-dependent enzymes in Parkinson's disease.
    Reichmann H; Janetzky B; Riederer P
    J Neural Transm Suppl; 1995; 46():157-64. PubMed ID: 8821051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron in parkinsonian and control substantia nigra--a Mössbauer spectroscopy study.
    Gałazka-Friedman J; Bauminger ER; Friedman A; Barcikowska M; Hechel D; Nowik I
    Mov Disord; 1996 Jan; 11(1):8-16. PubMed ID: 8771061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presymptomatic detection of Parkinson's disease.
    Jenner P
    J Neural Transm Suppl; 1993; 40():23-36. PubMed ID: 8294898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What process causes nigral cell death in Parkinson's disease?
    Jenner P
    Neurol Clin; 1992 May; 10(2):387-403. PubMed ID: 1584181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial DNA analysis in Parkinson's disease.
    Schapira AH; Holt IJ; Sweeney M; Harding AE; Jenner P; Marsden CD
    Mov Disord; 1990; 5(4):294-7. PubMed ID: 1979656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease.
    Faucheux BA; Martin ME; Beaumont C; Hunot S; Hauw JJ; Agid Y; Hirsch EC
    J Neurochem; 2002 Oct; 83(2):320-30. PubMed ID: 12423242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do alterations in glutathione and iron levels contribute to pathology associated with Parkinson's disease?
    Andersen JK
    Novartis Found Symp; 2001; 235():11-20; discussion 20-5. PubMed ID: 11280021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia.
    Dexter DT; Sian J; Jenner P; Marsden CD
    Adv Neurol; 1993; 60():273-81. PubMed ID: 8420143
    [No Abstract]   [Full Text] [Related]  

  • 19. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
    Hill WD; Arai M; Cohen JA; Trojanowski JQ
    J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in Parkinson's disease.
    Hattori N; Tanaka M; Ozawa T; Mizuno Y
    Ann Neurol; 1991 Oct; 30(4):563-71. PubMed ID: 1665052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.